ANGO benefits from NanoKnife, clinical milestones and a balanced portfolio despite tariff headwinds.
AngioDynamics posts narrower-than-expected Q1 loss, 12% revenue growth and margin gains; it also raises FY26 sales outlook, sending shares higher.
AngioDynamics, Inc. (NASDAQ:ANGO ) Q1 2026 Earnings Call October 2, 2025 8:00 AM EDT Company Participants James Clemmer - CEO, President & Director Stephen Trowbridge - Executive VP & CFO Conference Call Participants John Young - Canaccord Genuity Corp., Research Division Frank Takkinen - Lake Street Capital Markets, LLC, Research Division Eduardo Martinez-Montes - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good morning, and welcome to the AngioDynamics Fiscal Year 2026 First Quarter Earnings Call.
| Electronic Equipment, Instruments & Components Industry | Information Technology Sector | James C. Clemmer CEO | XFRA Exchange | US03475V1017 ISIN |
| US Country | 748 Employees | - Last Dividend | - Last Split | 27 May 2004 IPO Date |
AngioDynamics, Inc. is a prominent provider of invasive medical devices, catering to the needs of professional healthcare providers across the United States and internationally. The company specializes in a broad spectrum of medical areas, including vascular access, surgery, peripheral vascular disease, and oncology. Established in 1988, AngioDynamics is committed to enhancing patient outcomes through its innovative technologies and solutions, headquartered in Latham, New York.